Cargando…

Is the efficacy of remdesivir so different from that of lopinavir–ritonavir in severe COVID-19? The answer by real time-PCR: a narrative review

Detalles Bibliográficos
Autores principales:	Duarte, Tiago Isidoro, Vieira, Cesar, Pimentel, Carlos, Cascão, Mariana, Torre, Marta, Santos-Lima, Joaquim, Sequeira, Tânia, Germano, Nuno, Corte-Real, Rita, Bento, Luís
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165984/ https://www.ncbi.nlm.nih.gov/pubmed/35257569 http://dx.doi.org/10.5114/ait.2021.107894

Ejemplares similares

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review
por: Qomara, Windi Fresha, et al.
Publicado: (2021)

Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir
por: Yin, Guosheng, et al.
Publicado: (2020)

Lopinavir/ritonavir/remdesivir: Drug induced liver injury and off label use: 5 case reports
Publicado: (2020)

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
por: Sheahan, Timothy P., et al.
Publicado: (2020)

A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19
por: Maciorowski, Dawid, et al.
Publicado: (2020)

Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2
por: Uzunova, Katya, et al.
Publicado: (2020)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Propofol/lopinavir/ritonavir: Bradyarrythmia: case report
Publicado: (2020)

Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials
por: Izcovich, Ariel, et al.
Publicado: (2022)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
por: Ceccaldi, Pierre-François, et al.
Publicado: (2010)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Lopinavir/ritonavir: vomiting and watery diarrhoea: case report
Publicado: (2020)

Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
Publicado: (2020)

The administration of lopinavir/ritonavir via an enteral feeding tube()
por: Sirvent Segovia, Alejandro Esteban, et al.
Publicado: (2021)

Lichen planus after SARS-CoV-2 infection treated with lopinavir/ritonavir()
por: Gimeno Castillo, Javier, et al.
Publicado: (2021)

High rate of major drug–drug interactions of lopinavir–ritonavir for COVID-19 treatment
por: Macías, Juan, et al.
Publicado: (2020)

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
por: Chandwani, Ashish, et al.
Publicado: (2008)

Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
por: Reyskens, Kathleen M. S. E., et al.
Publicado: (2013)

Hydroxychloroquine/lopinavir/ritonavir: Exanthema and eosinophilia: 12 case reports
Publicado: (2020)

Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir
por: Mazan, Paula, et al.
Publicado: (2020)

Immunosuppressants/lopinavir/ritonavir interaction: Various toxicities: case report
Publicado: (2020)

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
por: Zhu, Zhen, et al.
Publicado: (2020)

Dexamethasone/hydroxychloroquine/lopinavir/ritonavir: Various toxicities: case report
Publicado: (2021)

Lopinavir/ritonavir/sotalol: Various toxicities: 9 case reports
Publicado: (2021)

Lopinavir/ritonavir delays COVID-19 recovery in paediatric patients
Publicado: (2022)

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
por: Ader, Florence, et al.
Publicado: (2021)

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study
por: Squires, Kathleen E., et al.
Publicado: (2011)

Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children
por: Martinez, Beatriz Larru, et al.
Publicado: (2010)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
por: Reyskens, Kathleen M. S. E., et al.
Publicado: (2013)

Outcomes related to 4864 pregnancies with exposure to lopinavir/ritonavir (LPV/r)
por: Tookey, Pat, et al.
Publicado: (2014)

Hypertriglyceridaemia and the risk of pancreatitis six months post lopinavir/ritonavir initiation
por: Greffrath, Wilhelm P., et al.
Publicado: (2018)

A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir
por: Joumaa, H., et al.
Publicado: (2020)

Hydroxychloroquine/lopinavir/ritonavir: Various side effects: 7 case reports
Publicado: (2020)

Lopinavir/ritonavir: Hyperlipidaemia following off-label use: case report
Publicado: (2020)

Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir
por: Rabie, Helena, et al.
Publicado: (2020)

Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer
por: Marima, Rahaba, et al.
Publicado: (2020)

Lopinavir/ritonavir: Bradyarrhythmia following an off-label use : case report
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_53fs3vf0m5vqjd8ec4uhk8dma6